References of "Daly, Adrian"
     in
Bookmark and Share    
See detailTSH-secreting pituitary adenoma in a male patient with a novel missense AIP mutation
Fajardo Montanana, C.; Daly, Adrian ULg; Tichomirova, M. A. et al

in The Endocrine Society's 91st Annual Meeting : 10-13 juin 2009, Washington (2009)

Detailed reference viewed: 15 (1 ULg)
See detailHigh Incidence of AIP mutations in sporadic pituitary adenomas in young patients with macroadenomas
Tichomirova, M. A.; Daly, Adrian ULg; Barlier, A. et al

in The Endocrine Society's 91st Annual Meeting : 10-13 juin 2009, Washington (2009)

Detailed reference viewed: 24 (2 ULg)
See detailCushing disease : Influence of microsurgery on hormonal balance
Vroonen, Laurent ULg; Martin, Didier ULg; Valdes Socin, Hernan Gonzalo ULg et al

in European Neuroendocrine Association - Workshop : Novel insights in the management of Cushing's syndrome (2009)

Detailed reference viewed: 19 (2 ULg)
See detailCushing disease : Pituitary microsurgery on hormonal balance
Stevenaert, Achille ULg; Vroonen, Laurent ULg; Perrin, G. et al

in European Neuroendocrine Association - Workshop : Novel insights in the management of Cushing's syndrome (2009)

Detailed reference viewed: 16 (1 ULg)
See detailThe Genetics in Cushing syndrome
Vandeva, S.; Daly, Adrian ULg; Vroonen, Laurent ULg et al

in European Neuroendocrine Association - Workshop : Novel experimental data on the pituitary and adrenal tumors responsible for Cushing's syndrome (2009)

Detailed reference viewed: 6 (0 ULg)
See detailCharacterization of prolatinomas resistant to dopaminergic agonists
Vroonen, Laurent ULg; Tamagno, G.; Naves, L. et al

in 19 Meeting of the Belgian Endocrine and Metabolic societies (2009)

Detailed reference viewed: 15 (2 ULg)
See detailFunctioning Pituitary Adenomas
Beckers, Albert ULg; Daly, Adrian ULg

in Refetoff, Samuel; Weiss, Roy E (Eds.) Genetic diagnosis of endocrine disorders (2009)

Detailed reference viewed: 6 (3 ULg)
See detailEpidémiologie des adénomes hypophysaires
Burlacu, M. C.; Daly, Adrian ULg; Beckers, Albert ULg

in Feuillets de Biologie (2009)

Les adénomes hypophysaires représentent une pathologie fréquente parmi les tumeurs cérébrales. Une étude liègoise récente a montré une prévalence des adénomes hypophysaires cliniquement actifs de 1:1064 ... [more ▼]

Les adénomes hypophysaires représentent une pathologie fréquente parmi les tumeurs cérébrales. Une étude liègoise récente a montré une prévalence des adénomes hypophysaires cliniquement actifs de 1:1064 habitants, nettement supérieure aux données antérieures. Tant dans les séries cliniques qu'autopsiques, les microadénomes à prolactine sont les adénomes prédominants. Les adénomes hypophysaires sont le plus souvent de présentation sporadique, mais des adénomes familiaux dans des formes isolées ou syndromiques sont également décrits. Les adénomes hypophysaires familiaux représentent 5 p.100 des adénomes hypophysaires et leur caractérisation clinique et génétique a été récemment enrichie par la description de la nouvelle entité FIPA (Familial Isolated Pituitary Adenomas) et des mutations du gène AIP (Aryl hydrocarbon receptor-Interactircg Protein). Bien que d'évolution habituellement bénigne, les adénomes hypophysaires sont caractérisés par une grande diversité clinique et génétique qui réclame des moyens diagnostiques et thérapeutiques spécifiques. [less ▲]

Detailed reference viewed: 13 (3 ULg)
Full Text
Peer Reviewed
See detailCaractérisation clinique et génétique des adénomes hypophysaires familiaux isolés (FIPA).
Beckers, Albert ULg; Apetrii, P.; Daly, Adrian ULg et al

in Revue Médicale de Liège (2009), 64(S1), 15-19

Pituitary adenomas are common brain tumours at autopsy and radiological series of unselected population. Historically, few epidemiologic data regarding the prevalence of clinically apparent pituitary ... [more ▼]

Pituitary adenomas are common brain tumours at autopsy and radiological series of unselected population. Historically, few epidemiologic data regarding the prevalence of clinically apparent pituitary adenomas have been available. Recently, a cross-sectional study conducted in Liege, Belgium, noted that clinically-apparent pituitary adenomas occurred with a prevalence of 1:1064 inhabitants, which is 3.5-5 times the previously reported prevalence. Pituitary adenomas occur predominantly as sporadic tumors, but also in a familial setting or associated to some familial/isolated tumoral syndromes. The recent characterization of the novel clinical entity FIPA (Familial Isolated Pituitary Adenomas) increased the prevalence of familial pituitary adenomas which account now for about 5% of pituitary tumors. Distinct genetic mechanisms are continuously identified and increase our understanding of the complex clinical presentation and sometimes unpredictable evolution of pituitary adenomas. [less ▲]

Detailed reference viewed: 85 (7 ULg)
Full Text
Peer Reviewed
See detailGenetic, molecular and clinical features of familial isolated pituitary adenomas.
Daly, Adrian ULg; Tichomirowa, M. A.; Beckers, Albert ULg

in Hormone Research (2009), 71(Suppl 2), 116-122

Pituitary adenomas occur in a familial setting in about 5% of all cases, and over half of these are due to multiple endocrine neoplasia type 1 (MEN1) and Carney's complex (CNC). Non-MEN1/CNC familial ... [more ▼]

Pituitary adenomas occur in a familial setting in about 5% of all cases, and over half of these are due to multiple endocrine neoplasia type 1 (MEN1) and Carney's complex (CNC). Non-MEN1/CNC familial pituitary tumours of all tumour phenotypes, known as familial isolated pituitary adenomas (FIPA), were first described in the late 1990s. Clinical features of FIPA differ from those of sporadic pituitary adenomas, as patients with FIPA have a younger age at diagnosis and larger tumours. About 15% of patients with FIPA have mutations in the aryl hydrocarbon receptor-interacting protein gene (AIP), which indicates that FIPA may have a diverse genetic pathophysiology. This article describes the clinical features of FIPA, the tumour pathologies found in this setting and the genetic/molecular data that have recently been reported in FIPA. [less ▲]

Detailed reference viewed: 14 (5 ULg)
Full Text
Peer Reviewed
See detailUpdate on the treatment of pituitary adenomas: familial and genetic considerations.
Daly, Adrian ULg; Beckers, Albert ULg

in Acta Clinica Belgica (2008), 63(6), 418-424

Clinically-relevant pituitary adenomas occur with a prevalence of approximately 1 per 1000 population in Belgium. Pituitary adenomas that occur in families are likely to have an important genetic ... [more ▼]

Clinically-relevant pituitary adenomas occur with a prevalence of approximately 1 per 1000 population in Belgium. Pituitary adenomas that occur in families are likely to have an important genetic pathophysiological basis. Currently about 5% of all pituitary adenoma cases have a family history of pituitary adenomas, classically due to multiple endocrine neoplasia type 1 (MEN1) and Carney complex (CNC). Over the last decade we have described non-MEN1/CNC familial pituitary tumours that include all tumour phenotypes, a condition named 'familial isolated pituitary adenoma' (FIPA). Clinical features of FIPA differ from those of sporadic pituitary adenomas in that patients with FIPA are often younger and have larger tumours at diagnosis. Approximately 15% of FIPA patients have mutations in the aryl hydrocarbon receptor interacting protein gene (AIP), which indicates that FIPA may have a diverse genetic pathophysiology. In this review we examine new findings on the epidemiology of pituitary adenomas and we review familial causes of pituitary adenomas with a particular emphasis on modern clinical testing. In addition, the clinical and genetic features of FIPA are described as FIPA represents a useful framework to study the features of pituitary adenomas that occur in a familial setting. [less ▲]

Detailed reference viewed: 28 (2 ULg)
See detailAn international, collaborative study of disease characteristics and response to therapy in 60 pituitary adenoma patients with Aryl Hydrocarbon Receptor Interacting
Tikhomirova, M.; Daly, Adrian ULg; Jaffrain-Réa, M. L. et al

in 18th Meeting of the Belgian Endocrine and Metabolic societies : Bruxelles, 25 octobre 2008 (2008, October)

Detailed reference viewed: 15 (5 ULg)
See detailTwo novel mutations of the calcium sensing receptor gene
Livaradiu, E.; Rydlewski, C.; Hamoir, Etienne ULg et al

in 18th Meeting of the Belgian Endocrine and Metabolic societies : Bruxelles, 25 octobre 2008 (2008, October)

Detailed reference viewed: 4 (0 ULg)
See detailCharacterization of prolatinomas resistant to dopaminergic agonists
Vroonen, Laurent ULg; Tamagno, G.; Naves, L. et al

in 18th Meeting of the Belgian Endocrine and Metabolic societies : Bruxelles, 25 octobre 2008 (2008, October)

Detailed reference viewed: 15 (2 ULg)
See detailCyclin dependant kinase inhibitor 1B (CDKN1B) gene mutations in familial isolated pituitary adenomas (FIPA) : Analysis in 84 families
Apetrii, P.; Tikhomirova, M.; Daly, Adrian ULg et al

in 18th Meeting of the Belgian Endocrine and Metabolic societies : Bruxelles, 25 octobre 2008 (2008, October)

Detailed reference viewed: 9 (0 ULg)
See detailAnatomo-pathological and genetic studies of adult McCune-Albright syndrome
Burlacu, M. C.; Thiry, Albert ULg; Livadariu, E. et al

in 18th Meeting of the Belgian Endocrine and Metabolic societies : Bruxelles, 25 octobre 2008 (2008, October)

Detailed reference viewed: 15 (0 ULg)
Full Text
Peer Reviewed
See detailCabergoline and the risk of valvular lesions in endocrine disease.
Lancellotti, Patrizio ULg; Livadariu, E.; Markov, M. et al

in European Journal of Endocrinology (2008), 159(1), 1-5

AIMS: The cardiac valvular risk associated with lower exposure to cabergoline in common endocrine conditions such as hyperprolactinemia is unknown. METHODS AND RESULTS: We performed a cross-sectional ... [more ▼]

AIMS: The cardiac valvular risk associated with lower exposure to cabergoline in common endocrine conditions such as hyperprolactinemia is unknown. METHODS AND RESULTS: We performed a cross-sectional, case-control echocardiographic study to assess the valvular status in 102 subjects receiving cabergoline for endocrine disorders and 51 matched control subjects. Cabergoline treatment ranged from 12 to 228 months, with a cumulative dose of 18-1718 mg. Valvular regurgitation was equally prevalent in both groups and was almost exclusively mild. Two cabergoline-treated subjects had moderate mitral regurgitation; there was no relationship between cabergoline dose and the presence or severity of mitral valve regurgitation (P=NS). Mitral valve tenting area was significantly greater in the cabergoline group when compared with the control subjects (P=0.03). Mitral valve leaflet thickening was observed in 5.9% of cabergoline-treated subjects; no relationship with the cumulative cabergoline dose was found. No patient had aortic or tricuspid valvular restriction. CONCLUSION: No significantly increased risk of clinically relevant cardiac valve disorders was found in subjects treated with long-term cabergoline therapy at the doses used in endocrine practice. While exposure to cabergoline appears to be safe during low-dose long-term therapy, an association with subclinical changes in mitral valve geometry cannot be completely excluded. [less ▲]

Detailed reference viewed: 36 (9 ULg)
Full Text
Peer Reviewed
See detailCurrent and future perspectives on Recombinant GH for the treatment of Obesity
Rixhon, M.; Tikhomirova, M. A.; Tamagno, G. et al

in Expert Review of Endocrinology & Metabolism (2008), 3(1), 75-89

The similarities between patients with untreated growth hormone (GH) deficiency and those with the cardiometabolic syndrome and the beneficial effects of recombinant human GH (rhGH) on body composition ... [more ▼]

The similarities between patients with untreated growth hormone (GH) deficiency and those with the cardiometabolic syndrome and the beneficial effects of recombinant human GH (rhGH) on body composition have led to the hypothesis that rhGH treatment may have utility in obesity. GH release is reduced in the setting of obesity, primarily due to hyperinsulinism and increased free fatty acid levels. We reviewed the outcomes of 23 clinical studies carried out between 1987 and 2006 that examined the effects of rhGH administration in the obese state. Typically, changes in overall body weight do not occur with rhGH therapy; however, assessment of body composition demonstrates reductions in visceral abdominal fat. Data on the effects of rhGH on lipid and carbohydrate metabolic profiles in obese patients are less clear-cut, with a subset of studies showing a beneficial effect and others a neutral effect. Given the increasing burden of obesity in the general population and the current paucity of effective therapies, it is useful to consider the data on rhGH and obesity from a clinical perspective to highlight potential treatment strategies that harness the somatotropic axis. [less ▲]

Detailed reference viewed: 16 (3 ULg)
Full Text
Peer Reviewed
See detailToll-like receptor-4 is expressed in meningiomas and mediates the antiproliferative action of paclitaxel.
Tichomirowa, Maria A.; Theodoropoulou, Marily; Daly, Adrian ULg et al

in International Journal of Cancer = Journal International du Cancer (2008), 123(8), 1956-63

Meningiomas are the second most common type of brain and CNS tumors by histology. Surgery and radiotherapy are main treatment options, but meningiomas may be impossible to adequately resect or may regrow ... [more ▼]

Meningiomas are the second most common type of brain and CNS tumors by histology. Surgery and radiotherapy are main treatment options, but meningiomas may be impossible to adequately resect or may regrow after surgery. In spite of many experimental attempts, there is no generally accepted chemotherapeutic approach. We have studied in a series of meningiomas the expression of the Toll-like receptor 4 (TLR4), which apart from its major role as a key factor of the innate immune system, is believed to play a role in tumorigenesis. All meningiomas studied expressed TLR4 mRNA and protein at variable degree. Paclitaxel, a ligand of TLR4, exhibited a dose- and time-dependent growth suppression in both monolayer and spheroid meningioma cell cultures. The knockdown of TLR4 with siRNA in meningioma cell cultures abrogated the inhibitory effect of paclitaxel. The suppressive action of paclitaxel on meningioma cell growth was enhanced in the presence of fluvastatin or the mitogen-actvated protein kinase (ERK1/2) inhibitor PD98059. At least part of the growth suppressive effect was mediated by the induction of apoptosis in meningioma cells by paclitaxel alone or in combination with fluvastatin. In conclusion, our in vitro results suggest that paclitaxel alone or in combination with other inhibitors of cell growth (statins, MAPK inhibitors) could provide a potential tool for the treatment of TLR4 expressing meningiomas. [less ▲]

Detailed reference viewed: 19 (4 ULg)
See detailAn International, Collaborative Study of the Disease Characteristics and Response to Therapy in 60 Pituitary Adenoma Patients with Aryl Hydrocarbon Receptor Interacting Protein (AIP) Gene Mutations
Daly, Adrian ULg; Tichomirowa, M. A.; Ebeling, T. M. L. et al

in ENDO 2008: 90th Annual Meeting of the Endocrine Society - Abstract book (2008)

Detailed reference viewed: 12 (2 ULg)